{"id":"https://genegraph.clinicalgenome.org/r/925db454-4d32-44c2-b41a-348a0f6400adv2.0","type":"EvidenceStrengthAssertion","dc:description":"PIGA was first reported in relation to X-linked complex neurodevelopmental disorder in 2012 (Johnston et al., PMID: 22305531). Pathogenic variants in PIGA result in a glycosyphosphatidylinositol (GPI) anchor protein defect, leading to a congenital disorder of glycosylation (CDG). The most common clinical presentation is infantile-onset developmental and epileptic encephalopathy with seizures that are refractory to treatment, myoclonus, hypotonia, severe to profound intellectual disability, characteristic facial features, and brain abnormalities (PMID: 32452540, 25885527). Liver, renal, and/or cardiac involvement, elevated alkaline phosphatase, ichthyosis or other skin manifestations, and systemic iron overload have been described in some patients, and early death can occur. Some individuals have a less severe clinical presentation consisting of mild to severe intellectual disability, developmental delay, and treatment-responsive seizures in the absence of involvement of other organs (PMID: 32452540, 25885527). \n\nPer criteria outlined by the ClinGen Lumping and Splitting Working Group, we found no difference in molecular mechanism, inheritance pattern, or phenotypic variability to support splitting the curation into different diseases. Therefore, the following disease entities have been lumped into one disease entity: multiple congenital anomalies-hypotonia-seizures syndrome 2 (OMIM: 300868, ORPHA:300496), malignant migrating focal seizures of infancy (ORPHA:293181), infantile epileptic spasms syndrome (ORPHA:3451), ferro-cerebro-cutaneous syndrome (ORPHA:397922), and neurodevelopmental disorder with epilepsy and hemochromatosis (OMIM: 301072). This curation does not address the association of somatic variants in PIGA with paroxysmal nocturnal hemoglobinuria (OMIM: 300818). \n\nThe ClinGen Epilepsy GCEP opted to curate this gene for complex neurodevelopmental disorder (MONDO:0100038) rather than congenital disorder of glycosylation (MONDO:0015286) to convey the specific phenotype of reported patients rather than curating for a more generic term (referring to a large group of disorders that can often only be diagnosed after the specific genetic etiology is known and are associated with a broad, nonspecific phenotypic spectrum.)\n\nThis curation includes more than 25 missense, nonsense, and frameshift variants reported in over 40 probands from 22 publications (PMIDs: 22305531, 24706016, 24259184, 24357517, 24259288, 25326635, 25885527, 25473036, 26545172, 26545172, 26993267, 27126216, 26923721, 29656098, 29414593, 29502866, 29974678, 28133863, 32452540, 32694024, 34875027, 36324500). More evidence is available in the literature, but the maximum score for genetic evidence (12 pts.) has been reached. The mechanism of pathogenicity is partial loss of function of an enzyme that is part of a complex that catalyzes the first step of GPI-anchor protein biosynthesis, and truncating variants are hypomorphic (PMID: 32452540). The gene-disease relationship is also supported by animal models (PMIDs: 37961693).\n\nIn summary, there is definitive evidence supporting the relationship between PIGA and X-linked complex neurodevelopmental disorder. This has been repeatedly demonstrated in both the research and clinical diagnostic settings and has been upheld over time. This classification was approved by the ClinGen Epilepsy GCEP on the meeting date April 16, 2024 (SOP Version 10). \n\nThis gene-disease pair was originally evaluated by the ClinGen Epilepsy GCEP on April 25, 2019. In 2024, the GCEP added several new papers and patients. As a result of this reevaluation, the classification changed from moderate to definitive.","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/925db454-4d32-44c2-b41a-348a0f6400ad","GCISnapshot":"https://genegraph.clinicalgenome.org/r/1fbb591b-eb34-4b73-a741-2f101886c896","calculatedEvidenceStrength":"Definitive","changes":[{"id":"cg:classificationChange"},{"id":"cg:summaryChange"},{"id":"cg:otherTextChange"},{"id":"cg:sopChange"},{"id":"cg:newEvidence"}],"contributions":[{"id":"https://genegraph.clinicalgenome.org/r/1fbb591b-eb34-4b73-a741-2f101886c896_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10005","date":"2024-10-07T19:33:16.139Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/1fbb591b-eb34-4b73-a741-2f101886c896_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10005","date":"2024-04-16T17:00:00.000Z","role":"Approver"}],"curationReasons":["RecurationTiming"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1fbb591b-eb34-4b73-a741-2f101886c896_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/13551a94-3697-425b-819b-1f94260a5209","type":"EvidenceLine","dc:description":"Variant also identified in affected brother. Mother is a heterozygous carrier.","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/13551a94-3697-425b-819b-1f94260a5209_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27126216","allele":{"id":"https://genegraph.clinicalgenome.org/r/96abd703-d382-4180-82e5-573c012c8734","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002641.3(PIGA):c.535A>T (p.Asn179Tyr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA412339267"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Hemizygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/9b8840a2-86db-497b-8b30-a53d640fae04","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9b8840a2-86db-497b-8b30-a53d640fae04_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24706016","allele":{"id":"https://genegraph.clinicalgenome.org/r/057a548a-4629-46cb-acf4-83276ae8923b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002641.4(PIGA):c.616A>T (p.Ile206Phe)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA156224"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Hemizygous"}},{"id":"https://genegraph.clinicalgenome.org/r/9b8840a2-86db-497b-8b30-a53d640fae04_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"PMID 24706016 performed flow cytometry of blood granulocytes from patients, which demonstrated reduced expression of GPI-anchored proteins. Expression of GPI-anchored proteins in PIGA-deficient JY5 cells was completely restored with the strong promoter (SRa)-driven I206F mutant PIGAs, whereas the weak promoter-driven mutant constructs only partially restored this function.  \n","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/6b6a561d-790d-47f3-8152-54643b4fb4d8","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6b6a561d-790d-47f3-8152-54643b4fb4d8_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26545172","allele":{"id":"https://genegraph.clinicalgenome.org/r/02672f2b-97ed-469d-a265-88de76ca76c9","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002641.4(PIGA):c.1234C>T (p.Arg412Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA128816"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Hemizygous"}},{"id":"https://genegraph.clinicalgenome.org/r/6b6a561d-790d-47f3-8152-54643b4fb4d8_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"PMID 22305531 included transfection of a mutant p.Arg412* PIGA construct into PIGA-null cells showed partial restoration of GPI-anchored proteins.  PMID 28441409 created a human induced pluripotent stem cell (hiPSC) model  that showed significant impairment of neuronal differentiation from neural progenitor cells generated by EB formation with decreased proliferation, aberrant synapse formation and abnormal membrane depolarization. ","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/f1fae27a-559d-4016-a658-e11bf87cfa1e","type":"EvidenceLine","dc:description":"Variant inherited from mother.","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f1fae27a-559d-4016-a658-e11bf87cfa1e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29656098","allele":{"id":"https://genegraph.clinicalgenome.org/r/d8088d2f-5e5a-4575-afe3-f34a8ddc5fb6","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002641.3(PIGA):c.356G>A (p.Arg119Gln)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA412340352"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Hemizygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/d23a1d69-f009-48b1-9295-df733136a112","type":"EvidenceLine","dc:description":"Variant is in the last exon so predicted to cause protein truncation, not NMD, but scoring full 2 pts since this is a recurrent variant identified in multiple unrelated patients and there is functional data. ","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d23a1d69-f009-48b1-9295-df733136a112_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22305531","allele":{"id":"https://genegraph.clinicalgenome.org/r/02672f2b-97ed-469d-a265-88de76ca76c9"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Hemizygous"}},{"id":"https://genegraph.clinicalgenome.org/r/d23a1d69-f009-48b1-9295-df733136a112_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"PMID 22305531 included transfection of a mutant p.Arg412* PIGA construct into PIGA-null cells showed partial restoration of GPI-anchored proteins. PMID 28441409 created a human induced pluripotent stem cell (hiPSC) model that showed significant impairment of neuronal differentiation from neural progenitor cells generated by EB formation with decreased proliferation, aberrant synapse formation and abnormal membrane depolarization. ","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/1fbb591b-eb34-4b73-a741-2f101886c896_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/399559b3-d6a7-4226-9ca5-b31737aa5878_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29974678","rdfs:label":"Family 1","estimatedLodScore":1.81,"family":{"id":"https://genegraph.clinicalgenome.org/r/399559b3-d6a7-4226-9ca5-b31737aa5878","type":"Family","rdfs:label":"Family 1"},"meetsInclusionCriteria":true,"phenotypePositiveAllelePositive":3,"phenotypes":["obo:HP_0001250","obo:HP_0001252","obo:HP_0001249"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/50b4acea-ba92-4183-8bc2-00449b17e17c"},"sequencingMethod":{"id":"cg:AllGenesSequencing"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/eceeae39-49f6-4e07-901e-7e49f450cdc9","type":"EvidenceLine","dc:description":"No variant level data to support pathogenicity","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/eceeae39-49f6-4e07-901e-7e49f450cdc9_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28133863","allele":{"id":"https://genegraph.clinicalgenome.org/r/381835cf-fc76-40cc-93b5-1c064f3739f9","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002641.3(PIGA):c.424G>A (p.Ala142Thr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA412340014"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Hemizygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/df64b28f-bdaa-4124-b17c-7c4f1c09751a","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/df64b28f-bdaa-4124-b17c-7c4f1c09751a_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26545172","allele":{"id":"https://genegraph.clinicalgenome.org/r/02672f2b-97ed-469d-a265-88de76ca76c9"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Hemizygous"}},{"id":"https://genegraph.clinicalgenome.org/r/df64b28f-bdaa-4124-b17c-7c4f1c09751a_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"PMID 22305531 included transfection of a mutant p.Arg412* PIGA construct into PIGA-null cells showed partial restoration of GPI-anchored proteins.  PMID 28441409 created a human induced pluripotent stem cell (hiPSC) model  that showed significant impairment of neuronal differentiation from neural progenitor cells generated by EB formation with decreased proliferation, aberrant synapse formation and abnormal membrane depolarization. ","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/fad59bf3-e671-4a67-b296-7c4ff9ec21ab","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/fad59bf3-e671-4a67-b296-7c4ff9ec21ab_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24706016","allele":{"id":"https://genegraph.clinicalgenome.org/r/02672f2b-97ed-469d-a265-88de76ca76c9"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Hemizygous"}},{"id":"https://genegraph.clinicalgenome.org/r/fad59bf3-e671-4a67-b296-7c4ff9ec21ab_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"PMID 22305531 included transfection of a mutant p.Arg412* PIGA construct into PIGA-null cells showed partial restoration of GPI-anchored proteins. PMID 28441409 created a human induced pluripotent stem cell (hiPSC) model that showed significant impairment of neuronal differentiation from neural progenitor cells generated by EB formation with decreased proliferation, aberrant synapse formation and abnormal membrane depolarization. This publication performed flow cytometry of blood granulocytes from patients, which demonstrated reduced expression of GPI-anchored proteins. Expression of GPI-anchored proteins in PIGA-deficient JY5 cells was only partially restored by transient expression with a weak TATA box promoter and there was complete\nrestoration of GPI-AP surface expression by the transfection of R412X mutant cDNA under the control of a strong promoter, suggesting that small amounts of full-length PIGA protein were generated by the readthrough of a stop codon because the cDNA truncated at R412 showed no activity.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/51d97cdb-1127-4dfd-966d-4ba561e18b52","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/51d97cdb-1127-4dfd-966d-4ba561e18b52_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32452540","allele":{"id":"https://genegraph.clinicalgenome.org/r/a228fcd6-c565-4cb8-b800-02d1b4e4a565","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002641.4(PIGA):c.56G>A (p.Arg19Gln)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA412341443"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Hemizygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/a455c8e1-3db1-4acc-b5c6-38bb4166d742","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a455c8e1-3db1-4acc-b5c6-38bb4166d742_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24706016","allele":{"id":"https://genegraph.clinicalgenome.org/r/ad463917-bfc2-4e01-86ef-3738c95a8b92","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002641.4(PIGA):c.355C>T (p.Arg119Trp)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA156219"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Hemizygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/94b8fcbb-230d-4406-bb10-d3b34d5c9a58","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/94b8fcbb-230d-4406-bb10-d3b34d5c9a58_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/36324500","allele":{"id":"https://genegraph.clinicalgenome.org/r/c203fd51-ad2c-4926-a002-fe1dc431a5ee","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002641.4(PIGA):c.145G>A (p.Val49Met)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA412341153"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Hemizygous"}},{"id":"https://genegraph.clinicalgenome.org/r/94b8fcbb-230d-4406-bb10-d3b34d5c9a58_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"To determine the functional impact of the c.145G>A (p.Val49Met) variant, granulocyte expression of CD16 was determined by flow cytometry and rescue analysis in the PIGA-KO HEK293 cells. A 13% reduction in CD16 was observed in the patient compared to the healthy control (Figure 3A). Rescue of CD59 expression by the variant was found to be significantly deficient (62% of wild type; p < 0.001). Rescue of DAF expression was also found to be significantly deficient (73% of wild type; p < 0.001) (Figure 3B).","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/bc75893c-0b74-41a1-aa82-d6ca0fac73d7","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/bc75893c-0b74-41a1-aa82-d6ca0fac73d7_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/34875027","allele":{"id":"https://genegraph.clinicalgenome.org/r/852db187-cdde-4b6b-9913-0c661caee256","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002641.4(PIGA):c.380C>T (p.Ser127Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA412340287"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Hemizygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/c7e9ccab-9eb1-4718-b30d-78644d0e2de3","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c7e9ccab-9eb1-4718-b30d-78644d0e2de3_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/34875027","allele":{"id":"https://genegraph.clinicalgenome.org/r/ff610fcf-737b-4643-b383-42e8b7c8c304","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002641.4(PIGA):c.230G>A (p.Arg77Gln)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA10354177"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Hemizygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/57635cdc-0092-4dd9-8226-bad18ff1a6ad","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/57635cdc-0092-4dd9-8226-bad18ff1a6ad_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25473036","allele":{"id":"https://genegraph.clinicalgenome.org/r/3e75bb9f-7202-484e-aa6c-9d708d7e5607","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002641.4(PIGA):c.68dup (p.Ser24LysfsTer6)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA10581332"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Hemizygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/2201d254-2876-4606-b29e-e5a66661a75e","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2201d254-2876-4606-b29e-e5a66661a75e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32452540","allele":{"id":"https://genegraph.clinicalgenome.org/r/581984a3-a99f-4736-a60b-a9f664272099","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002641.4(PIGA):c.986T>C (p.Val329Ala)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA412336104"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Hemizygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/cdfa5a7c-35cc-4fe5-9473-9bbfda05ba30","type":"EvidenceLine","dc:description":"Epilepsy not noted in phenotype","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cdfa5a7c-35cc-4fe5-9473-9bbfda05ba30_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25326635","allele":{"id":"https://genegraph.clinicalgenome.org/r/38cc75f8-9c2c-4908-990f-f1d3bb228958","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002641.4(PIGA):c.241C>T (p.Arg81Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA412340936"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Hemizygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/f06cd98b-7f3f-455e-af1f-8217be8717d0","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f06cd98b-7f3f-455e-af1f-8217be8717d0_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29974678","allele":{"id":"https://genegraph.clinicalgenome.org/r/685cc1b4-7228-4c0a-8575-4676a8f84eac","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002641.4(PIGA):c.849-5A>G","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2695231410"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Hemizygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/7c407a80-f0dd-4575-8afa-f96b853fea0e","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7c407a80-f0dd-4575-8afa-f96b853fea0e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32694024","allele":{"id":"https://genegraph.clinicalgenome.org/r/7bf6580a-7d48-40e9-85ce-855a0a81e83d","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002641.4(PIGA):c.1178G>T (p.Arg393Ile)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA412335029"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Hemizygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/d7af105c-ce57-464c-9679-6e4fb33f968e","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d7af105c-ce57-464c-9679-6e4fb33f968e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25885527","allele":{"id":"https://genegraph.clinicalgenome.org/r/6dd041fa-a4c6-4bf2-ac9d-293af2f5f836","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002641.3(PIGA):c.989G>A (p.Ser330Asn)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA412336090"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Hemizygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/13530fa6-e9d5-4899-a821-b0058ac1eabd","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/13530fa6-e9d5-4899-a821-b0058ac1eabd_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29502866","allele":{"id":"https://genegraph.clinicalgenome.org/r/3c0964a9-c518-41e9-b49b-4dd1570c993f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002641.3(PIGA):c.110T>C (p.Met37Thr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA412341236"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Hemizygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/e2c1568e-554f-49aa-a26f-1bfa8926df84","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e2c1568e-554f-49aa-a26f-1bfa8926df84_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26993267","allele":{"id":"https://genegraph.clinicalgenome.org/r/a51c70a8-d336-48f8-b931-1ccde5cd63a4","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002641.3(PIGA):c.1064T>C (p.Leu355Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA412335555"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Hemizygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/c51dbdbd-2422-49d0-9295-c188a6686989","type":"EvidenceLine","dc:description":"inherited from mother","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c51dbdbd-2422-49d0-9295-c188a6686989_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29414593","allele":{"id":"https://genegraph.clinicalgenome.org/r/c497ecbc-6f15-4c89-992c-80ca9c269cc1","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002641.3(PIGA):c.293A>C (p.Tyr98Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA412340695"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Hemizygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/71ef4d62-cb3d-48a3-b1a5-3ec842605331","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/71ef4d62-cb3d-48a3-b1a5-3ec842605331_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24259288","allele":{"id":"https://genegraph.clinicalgenome.org/r/8d2ba9ac-9a20-4c8f-afeb-c922faa28cf5","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002641.4(PIGA):c.1030_1032del (p.Leu344del)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA156226"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Hemizygous"}},{"id":"https://genegraph.clinicalgenome.org/r/71ef4d62-cb3d-48a3-b1a5-3ec842605331_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Using flow cytometry to analyze blood cells from patient IV-3, the authors demonstrated reduced cell surface expression of CD24 and GPI-specific staining suggesting a reduction in GPI-anchored proteins on granulocytes (Figure 11A). No difference was seen when looking at cell-specific markers for monocytes and red blood cells (Figure 11B,C). These results suggest a cell-type dependent reduction but not a complete loss of PIGA activity in granulocytes.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/1311d012-913f-4f50-9d6d-14d2ab2aa6be","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1311d012-913f-4f50-9d6d-14d2ab2aa6be_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32694024","allele":{"id":"https://genegraph.clinicalgenome.org/r/e9f711d2-6481-4300-b655-a1a5d475485f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002641.4(PIGA):c.565A>G (p.Lys189Glu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA412339109"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Hemizygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/db847e3e-94ab-4a08-843b-d230ffe82511","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/db847e3e-94ab-4a08-843b-d230ffe82511_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24357517","allele":{"id":"https://genegraph.clinicalgenome.org/r/e9487867-50c0-45bc-98f3-2a77956e3a35","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002641.4(PIGA):c.76dup (p.Tyr26LeufsTer4)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA156221"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Hemizygous"}},{"id":"https://genegraph.clinicalgenome.org/r/db847e3e-94ab-4a08-843b-d230ffe82511_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"This is a frameshift early in the PIGA cDNA. CD59 surface expression suggested the production of a shorter PIGA protein with residual functionality, and studies suggest the second methionine at position 37 may be used for the translation of a 36 amino acids shorter PIGA. Complementation assays confirmed that this shorter PIGA cDNA was able to partially rescue the surface expression of CD59 in a PIGA-null cell line. ","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/dc11f99f-ad67-4d45-a5e4-f9d91165a0b5","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/dc11f99f-ad67-4d45-a5e4-f9d91165a0b5_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26923721","allele":{"id":"https://genegraph.clinicalgenome.org/r/ad190143-98f3-44c9-ac5a-f6c1f6a97082","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002641.3(PIGA):c.427A>G (p.Lys143Glu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA412339998"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Hemizygous"}},{"id":"https://genegraph.clinicalgenome.org/r/dc11f99f-ad67-4d45-a5e4-f9d91165a0b5_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"The surface expression levels of GPI-anchored proteins were analyzed on blood cells from the proband and his mother: CD16 and CD59 on red blood cells (RBCs) and CD16 and fluorescent aerolysin on white blood cells (WBCs). The cells were stained with appropriate antibodies and analyzed by flow cytometry (FC500, Beckman Coulter, Fullerton, CA, USA). The surface expression of RBC CD16 was significantly decreased in the proband (by 11.0%) and his mother (by 15.6%), relative to the normal levels in healthy controls. However, the expression levels of other GPI-anchored proteins on RBCs and WBCs were all equivalent to the normal levels (Fig. S4).","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/52f5ae1b-bf17-4d5d-afac-f97dc12dafb8","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/52f5ae1b-bf17-4d5d-afac-f97dc12dafb8_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24706016","allele":{"id":"https://genegraph.clinicalgenome.org/r/103c0e5b-d353-42c4-b59f-60c19afd987d","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002641.4(PIGA):c.230G>T (p.Arg77Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA156222"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Hemizygous"}},{"id":"https://genegraph.clinicalgenome.org/r/52f5ae1b-bf17-4d5d-afac-f97dc12dafb8_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"PMID 24706016 performed flow cytometry of blood granulocytes from patients, which demonstrated reduced expression of GPI-anchored proteins. Expression of GPI-anchored proteins in PIGA-deficient JY5 cells was completely restored with the strong promoter (SRa)-driven R77L mutant PIGAs, whereas the weak promoter-driven mutant constructs only partially restored this function.  ","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/2aa3bc8e-4d4f-4d0d-bacf-204b51d7dfb6","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2aa3bc8e-4d4f-4d0d-bacf-204b51d7dfb6_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24259184","allele":{"id":"https://genegraph.clinicalgenome.org/r/82409376-4705-4af9-9152-feb64eb72876","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002641.4(PIGA):c.278C>T (p.Pro93Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA156230"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Hemizygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12},{"id":"https://genegraph.clinicalgenome.org/r/1fbb591b-eb34-4b73-a741-2f101886c896_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1fbb591b-eb34-4b73-a741-2f101886c896_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/265aee70-ce18-4b70-acc1-7d5e58365055","type":"EvidenceLine","dc:description":"While an effect is demonstrated, the relationship of this effect to epilepsy and neurodevelopmental disability is speculative.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/57a6598e-d098-4dc6-84ca-ab8413a08488","type":"Finding","dc:description":"The model demonstrates alterations in characteristics of neurons, the relevant substrate for the human neurological phenotype.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28441409","rdfs:label":"PIGA iPSCs","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityCellCultureModelOrganismCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/9ccd08c8-bd5b-4e98-ab3e-6dc882972453","type":"EvidenceLine","dc:description":"Downgrading since drosophila are not a well established model for human seizures (non-vertebrate). ","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9cb6c0d5-cc35-4757-a2b2-9c2eddfa5bc1","type":"Finding","dc:description":"While evaluating climbing ability as a general measure of neurological function, a subset of flies were noted to have seizure-like activity preventing climbing activity. Performed the bang-sensitive assay (commonly used measure of seizure susceptibility in flies) which showed 35% of PIG-A+/âˆ’ flies have seizure activity compared with zero seizures in the WT flies. Neuron-specific knockdown resulted in reduced lifespan and neurological phenotypes but no seizures while glia-knockdown reduced lifespan and resulted in a seizure phenotype in 70%. The human phenotype includes seizures in nearly all patients reported so far (PMID 25326635 reports a patient not noted to have seizures) whereas only a subset of flies have seizures.\n","dc:source":"https://pubmed.ncbi.nlm.nih.gov/37961693","rdfs:label":"Drosophila models of PIGA-CDG","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":0.5}],"evidenceStrength":"Definitive","sequence":9123,"specifiedBy":"GeneValidityCriteria10","strengthScore":12.5,"subject":{"id":"https://genegraph.clinicalgenome.org/r/MO6uuw2SHkY","type":"GeneValidityProposition","disease":"obo:MONDO_0100038","gene":"hgnc:8957","modeOfInheritance":"obo:HP_0001417"},"version":"2.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_1fbb591b-eb34-4b73-a741-2f101886c896-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}